Advanced ovarian cancer: Update, remarks and conclusions on optimal therapy

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 57-60

  Poveda, A ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Advanced ovarian cancer; Optimal therapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GYNECOLOGIC SURGERY; HUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033999633     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99513.x     Document Type: Article

References (32)

1. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353 (9160): 1207-10.
2. Mackay J. Cancer genetics: breast and ovary. In: Educational Book, 23rd ESMO Congress. Athens, 1998; 3-6.
3. Greggi S, Genuardi M, Benedetti-Panici P et al. Analysis of 138 consecutive ovarian cancer patient: incidence and characteristics of familial cases. Gynecol Oncol 1990; 39: 300-4.
4. Bast RC Jr, Yu Y, Xu FJ et al. Molecular approaches to the management of epithelial ovarian cancer. Int J Gynecol Cancer 2000; 10(Suppl. 1): 2-7.
5. Izquierdo MA, Van der Zee AGJ, Vermorken JB et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-7.
6. Eisenhauer EA. New cytotoxics and non-cytotoxics in epithelial ovarian cancer, Int J Gynecol Cancer 2000; 10 (Suppl. 1): 38-43.
7. Arts HJG, van der Zee AGJ, de Jong S, de Vries EGE. Options for modulation of drug resistance in ovarian cancer, Int J Gynecol Cancer 2000; 10(Suppl. 1): 47-52.
8. Ueno NT, Hung MC, Zhang S et al. Phase I E1A gene therapy in patients with advanced breast and ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 432 (abstract).
9. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-4.
10. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8.
11. Trimbos JB, Bolis G. Guidelines for surgical staging of ovarian cancer. Obstet Gynecol Surv 1994; 49: 814-6.
12. Trimbos JB. Staging of early ovarian cancer and the impact of lymph node staging, Int J Gynecol Cancer 2000; 10 (Suppl. 1): 8-11.
13. Van Oosterom AT. Improving cancer survival in the next century. Eur J Cancer 1997; 33 (Suppl.4): S1-S6.
14. Eisenkop SM, Spirto NM, Montag TW et al. The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203-9.
15. Junor EJ, Hole DR, McMurty L et al. Specialist gynaecologists and survival outcomes in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999; 106: 1130-6.
16. Van der Burg MEL, Van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Eng J Med 1995; 332: 629-34.
17. Pecorelli S. Secondary cytoreductive surgery and palliative surgery in advanced ovarian cancer. Proceedings 1st International Symposium Advanced Ovarian Cancer: Optimal Therapy Valencia.
18. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Eng J Med 1996; 334: 1-6.
19. Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer. Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998; 17: 361a.
20. Ozols RF, Bundy BN, Fowler J et al. Randomized phase III study of cisplatin/paclitaxel versus carboplatin/ paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999; 8: 356 (abstract).
21. Dubois A, Lueck HJ, Meier W et al. Cisplatin/Paclitaxel vs Carboplatin/Paclitaxel in Ovarian Cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol 1999; 8: 356 (abstract).
22. Hoskins P, Eisenhauer E, Fisher B et al. Sequential couplets of cisplatin/topotecan and cisplatin/paclitaxel as first-line therapy for advanced epithelial ovarian cancer: an NCI-C Clinical Trials Group Phase II study. Proc Am Soc Clin Oncol 1999; 8: 357 (abstract).
23. Kaye SB. Intravenous chemotherapy for ovarian cancer - the state of the art? Int J Gynecol Cancer 2000; 10:(Suppl. 1): 19-25.
24. Kaye SB. Is there any impact of new drugs on the outcome of treatment for ovarian cancer? In Educational Book, 23rd ESMO Congress 1998; 3-6.
25. Alberts DS, Liu PY, Hanningan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Eng J Med 1996; 335: 1950-5.
26. Markman M, Bundy B, Benda T et al. Randomized phase 3 study of iv cisplatin/paclitaxel versus moderate high dose iv carboplatin followed by iv paclitaxel and ip in optimal residual ovarian cancer. An Intergroup trial. Proc Am Soc Clin Oncol 1998; 17: 361 (abstract).
27. Vermorken JB. The role of intraperitoneal chemotherapy in ovarian cancer. Int J Gynecol Cancer 2000; 10(Suppl. 1): 26-32.
28. Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 2000; 10(Suppl. 1): 33-37.
29. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 2000; 10(Suppl. 1): 44-46.
30. Ledermann JA, Herd R, Maranchini D et al. High dose chemotherapy in ovarian cancer: an analysis of the experience of the European Group for Blood and Marrow Transplantation (EBMT) over 7 years. Proc Am Soc Clin Oncol 1999; 18: 360 (abstract).
31. Ledermann JA. High dose chemotherapy with PBSCT in ovarian cancer, Int J Gynecol Cancer 2000; 10(Suppl. 1): 53-56.
32. Berek JS, Bertelsen K, du Bois A et al. Advanced ovarian cancer: 1998 consensus statements. Ann Oncol 1998; 10 (Suppl.1): S87-S92.